Literature DB >> 34330737

177Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.

Johannes Czernin1, Jeremie Calais1.   

Abstract

Entities:  

Keywords:  177Lu-PSMA 617; Oncology: GU; Other; PSMA; VISION trial

Mesh：

Substances：

Year:  2021        PMID： 34330737     DOI： 10.2967/jnumed.121.262710

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  5 in total

1.  To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.

Authors:  Sandy Srinivas; Andrei Iagaru
Journal:  J Nucl Med       Date:  2021-08-26       Impact factor: 10.057

2.  Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T.

Authors:  Lena M Unterrainer; Leonie Beyer; Mathias J Zacherl; Franz J Gildehaus; Andrei Todica; Sophie C Kunte; Adrien Holzgreve; Gabriel T Sheikh; Annika Herlemann; Jozefina Casuscelli; Matthias Brendel; Nathalie L Albert; Vera Wenter; Nina-Sophie Schmidt-Hegemann; Wolfgang G Kunz; Clemens C Cyran; Jens Ricke; Christian G Stief; Peter Bartenstein; Harun Ilhan; Marcus Unterrainer
Journal:  Biomedicines       Date:  2022-04-20

Review 3.  Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas.

Authors:  Tomas Etrych; Alena Braunova; David Zogala; Lukas Lambert; Nicol Renesova; Pavel Klener
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

Review 4.  Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.

Authors:  Susan J Keam
Journal:  Mol Diagn Ther       Date:  2022-05-13       Impact factor: 4.476

Review 5.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.